Philogen S.p.A. is the older company (1996 vs 1997); Xencor is the larger of the two.
Side-by-Side Comparison
| Metric | Philogen S.p.A. | Xencor |
|---|---|---|
| Founded | ||
| Founded | 1996 older | 1997 |
| Headquarters | ||
| Headquarters | Sovicille, Italy | Pasadena, United States |
| Employees | ||
| Employees | 184 | 303 larger |
| Industry | ||
| Industry | Biotechnology, Pharmaceutical | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | IPO | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $130.84M | $482.60M |
| Funding Rounds | ||
| Funding Rounds | 2 | 11 |
| Services | ||
| Services | Innovative cancer treatment development, Therapeutic and imaging radio conjugate production, Scientific research and drug development | Design and development of bispecific antibody drugs, Strategic collaborations with pharmaceutical companies, Extensive clinical and preclinical drug pipeline, Customization of antibodies using XmAb protein engineering platform |
| Target Customers | ||
| Target Customers | Medical professionals, Pharmaceutical companies, Cancer treatment centers, Healthcare providers, Research institutions | Pharmaceutical companies interested in drug development partnerships, Investors seeking opportunities in biotechnology and life sciences, Healthcare professionals focused on cancer and serious disease therapeutics, Scientific research communities involved in antibody and protein engineering |
| Taxonomy | ||
| Taxonomy | Biopharmaceuticals, Angiogenesis, Monoclonal Antibodies, Cancer Therapy, Rheumatoid Arthritis Treatment, Age-related Macular Degeneration, Tumor Neo-vasculature Targeting, Antibody Derivatives, Clinical Trials, GMP Production, R&D, Patent Portfolio, Pharmaceutical Partnerships, Biotechnology Innovator | Protein Engineering, Antibody Therapeutics, Biotherapeutics, Autoimmune Disease Treatment, Oncology, Asthma Treatment, B Cell Malignancies, Hodgkin's Lymphoma, Myeloma Treatment, Biosuperiors, Monoclonal Antibodies, Bispecific Antibodies, Drug Development, Cytokines, Neuroinflammatory Diseases |
| Website | ||
| Website | philogen.com | xencor.com |
About Philogen S.p.A.
Philogen S.p.A., founded in 1996, is a Swiss-Italian biotechnology company with a focus on developing advanced biopharmaceuticals aimed at treating disorders related to angiogenesis. Angiogenesis, the formation of new blood vessels, is a process commonly found in severe conditions like cancer, rheum...
About Xencor
Xencor, founded in 1997, is at the forefront of the biotechnology sector, revolutionizing treatments for autoimmune diseases, asthma, and cancer through cutting-edge biotherapeutics. Their slogan, "Proteins by Design", encapsulates their innovative approach towards protein engineering. Leveraging t...
We will tell you when either one moves
BounceWatch watches Philogen S.p.A. and Xencor for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Philogen S.p.A. and Xencor — by email.
Frequently Asked Questions
Compare Philogen S.p.A. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Philogen S.p.A. on 15 Jun 2026, and Xencor on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.